Status:
COMPLETED
Prolonged Multimodal Analgesia for Post-Discharge Pain Control After Primary Total Hip Arthroplasty
Lead Sponsor:
Rothman Institute Orthopaedics
Conditions:
Osteoarthritis, Hip
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective, three-arm, comparative study with a provider-crossover design. The first arm will comprise the standard of care pain regimen after discharge, which comprises PRN oxycodone, tram...
Eligibility Criteria
Inclusion
- Patients undergoing unilateral, primary cementless THA with underlying diagnosis of osteoarthritis.
- ASA I - III
- Spinal anesthesia
- Male and Female over 18 who are willing and able to provide informed consent
Exclusion
- Opioid use within 3 months prior to surgery
- General anesthesia
- Non-english speaking
- ASA IV or greater
- Allergy/contraindications to protocol medications
- Renal insufficiency with Cr \> 2.0 or hepatic failure
- Sensory/motor disorder involving the operative limb
- Planned or unplanned discharge to rehab
- Length of stay \>3 days
- Revision or conversion THA
- Cigarette smokers
Key Trial Info
Start Date :
June 5 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2018
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT03358888
Start Date
June 5 2017
End Date
February 28 2018
Last Update
January 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rothman Institute
Philadelphia, Pennsylvania, United States, 19107